Unique ID issued by UMIN | UMIN000008360 |
---|---|
Receipt number | R000009830 |
Scientific Title | Blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB) |
Date of disclosure of the study information | 2012/08/01 |
Last modified on | 2017/06/27 13:36:24 |
Blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB)
ECO Tablet trial
Blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB)
ECO Tablet trial
Japan |
the hypertensive patient who has taken ARB and CCB
Cardiology |
Others
NO
We investigate tne blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB).
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
change of systolic blood pressure at a medical office
change of diastololic blood pressure at a medical office, blood presssure at home, compliance of drug
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
To the hypertensive patient who has taken azelnidipine 16mg/day and olmesartan 20mg/day, or amlodipine 5mg/day and olmesartan 20mg/day, respectively, more than one month (4 weeks), we replace one compound drug(Rezaltas HD) that ingredient is azelnidipine 16mg and olmesartan 20mg.
20 | years-old | <= |
Not applicable |
Male and Female
a) the hypertensive patient who has taken azelnidipine 16mg/day and olmesartan 20mg/day, or amlodipine 5mg/day and olmesartan 20mg/day, respectively, more than one month (4 weeks).
b)the patient whose blood pressure at a mediacl office is below 159/99mmHg.
c)the patinet above 20 years-old.
a) patient with previous allergic reaction to azelnidipine or olmesartan.
b) female patient who has possibility of pregnancy.
c) patient treated with azole antifungal drug or HIV protease inhibitor.
d) patient who has taken hemodialysis or has severe renal dysfunction (serume creatine level is above 2.0mg/dL).
e) patient considered to be improper to this study by attending doctor.
200
1st name | |
Middle name | |
Last name | Hiroshi Ito |
Okayama Univesity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Department of Cardiovascular Medicine
2-5-1, Shikata-cho, Kita-ku, Okayama
086-235-7349
itomd@md.okayama-u.ac.jp
1st name | |
Middle name | |
Last name | Kunihisa Kohno |
Okayama Univesity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Department of Cardiovascular Medicine
2-5-1, Shikata-cho, Kita-ku, Okayama
086-235-7351
kunihisakohno@msn.com
Department of Cardiovascular Medicine, Okayama Univesity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
The adult cardiovascular reserch foundation
Non profit foundation
Japan
NO
あしもりクリニック(岡山県)、井上クリニック(兵庫県)、井原市民病院(岡山県)、庵谷医院(岡山県)、井村医院(岡山県)、氏平医院(岡山県)、岡山医療センター(岡山県)、岡山光南病院(岡山県)、岡山済生会総合病院(岡山県)、岡山市立市民病院(岡山県)、岡山赤十字病院(岡山県)、岡山大学病院(岡山県)、岡山ハートクリニック(岡山県)、香川県立中央病院(香川県)、香川成人医学研究所附属診療所(香川県)、香川労災病院(香川県)、笠岡市立市民病院(岡山県)、笠岡第一病院(岡山県)、かじやま内科循環器科(広島県)、鴨方クリニック(岡山県)、草加病院(岡山県)、康愛クリニック(岡山県)、河野医院(広島県)、小林内科診療所(岡山)、心臓病センター榊原病院(岡山県)、杉江医院(岡山県)、住友別子病院(愛媛県)、高松大林病院(香川県)、高松赤十字病院(香川県)、時末消化器科内科医院(岡山県)、なかやまクリニック(岡山県)、難波医院(岡山県)、長谷川紀念病院(岡山県)、はせ川内科循環器科医院(香川県)、姫路赤十字病院(兵庫県)、広島逓信病院(広島県)、福嶋医院(岡山県)、福山医療センター(広島県)、福山市民病院(広島県)、ふよう内科クリニック(岡山県)、松原クリニック循環器科内科(山口県)、松山市民病院(愛媛県)、南坊井上内科循環器科医院(広島県)、山下産婦人科内科医院(広島県)、山中医院(岡山県)、山成医院(岡山県)
2012 | Year | 08 | Month | 01 | Day |
Published
Completed
2012 | Year | 05 | Month | 23 | Day |
2012 | Year | 07 | Month | 01 | Day |
2015 | Year | 10 | Month | 31 | Day |
2012 | Year | 07 | Month | 05 | Day |
2017 | Year | 06 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009830